Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

5Total
Not Applicable (3)
P 1 (1)
P 3 (1)

Trial Status

Recruiting4
Unknown1
Not Yet Recruiting1
Terminated1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07084519Phase 3Recruiting

Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction

NCT07616297Not ApplicableRecruiting

Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients

NCT06115811Not ApplicableNot Yet RecruitingPrimary

Radiation Treatment Plan Evaluation Learning Tool Pilot Project

NCT05176964Unknown

Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer

NCT03734952Not ApplicableRecruitingPrimary

Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy

NCT03466424RecruitingPrimary

Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer

NCT01441115Phase 1Terminated

ECI301 and Radiation for Advanced or Metastatic Cancer

Showing all 7 trials

Research Network

Activity Timeline